Assembling the evidence…
Gradual extension of injection intervals of lanadelumab presented in this study can minimize the burden of therapy without losing efficacy.
causal efficacy-preservation wording exceeds the selected uncontrolled design and documented breakthrough attacks
On average, the angioedema control test values improved from 7.5 (poorly controlled disease) to 14.9 (well-controlled disease), and all patients showed adequate disease control.
paired observations support the direction and magnitude, although the uncontrolled before–after design limits attribution
Twenty-two patients were symptom-free from the beginning of the treatment phase and intended to extend their injection interval from 30 to 32.5 days (median).
directly reported descriptive result from the monitored cohort
Derived from the full evaluation — not a separate score.
Strengths
Figure 1 specifies when to extend intervals, how quickly to do so, and when breakthrough symptoms require returning to the prior symptom-free interval.
↳ Methods, “Treatment and procedure for extension of injection intervals,” and Figure 1
Disease control and quality of life are assessed with the validated AECT and AE-QoL instruments, with paired observations reported for available patients.
↳ Methods, “Patient-reported outcome measures”; Results, Figures 4–6
The Discussion compares baseline and follow-up AE-QoL values with Hahn and Lumry rather than merely citing them, and explains why AE-QoL was selected over HAE-QoL.
↳ Discussion, pp. 3748–50
Limitations
Patients switched because of inadequate control, impaired quality of life, or treatment burden, and interval extension began only after symptom freedom. Without a comparator or adjustment strategy, treatment and protocol effects cannot be isolated from selection and regression to the mean.
↳ Methods, “Patients” and “Treatment and procedure,” pp. 3745–46
The conclusion says burden can be reduced “without losing efficacy,” although eight patients had more than one attack during prolongation and three required shorter intervals.
↳ Results, p. 3746; Conclusions, pp. 3744 and 3750
Three AE-QoL subdomain point estimates fall outside their stated 95% confidence intervals, preventing reliable interpretation of those domain-specific precision estimates.
↳ Results, “Lanadelumab treatment significantly improves quality of life,” pp. 3747–48
The study’s main value lies in Figure 1’s reproducible interval-adjustment algorithm and its application in routine specialist care. The AECT and overall AE-QoL results indicate substantial observed improvement, but treatment selection and symptom-free eligibility for extension make causal interpretation difficult. The conclusion overstates preserved efficacy because breakthrough attacks were part of titration and some patients required interval shortening. Quantitative engagement with prior studies supports the paper’s context, while the omitted design limitation and inconsistent subdomain confidence intervals temper confidence.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.6
Confidence mediumThe study contributes a concrete three-day interval-extension algorithm and real-world observations in 34 patients, including four with acquired C1-inhibitor deficiency. Its advance is useful but incremental beside established trial efficacy and earlier real-world evidence.
“we present our approach for extending injection intervals of lanadelumab”
Validated AECT and AE-QoL instruments, explicit adjustment rules, and patient-level interval reporting make the cohort reconstructible. Treatment selection based on poor control and extension conditional on symptom freedom are not addressed through a comparator or confounding strategy, yet the conclusion attributes preserved efficacy to the protocol.
“can minimize the burden of therapy without losing efficacy”
The article proceeds coherently from clinical rationale through protocol, outcomes, and comparison with prior studies. Precision is reduced by incompatible AE-QoL subdomain confidence intervals and by the headline efficacy-preservation wording despite documented breakthrough attacks.
“Eight patients had more than 1 attack during the interval prolongation”
The Discussion quantitatively compares the cohort with Hahn, Lumry, and phase 3 evidence and explains the choice of AE-QoL. The limitations paragraph reports missing baseline data but does not trace the uncontrolled, selected design through to the early-extension recommendation.
“We report on the following limitations of this study”
Caveats4 of 4 checks
Several AE-QoL subdomain point estimates are incompatible with their reported confidence intervals, but the overall AE-QoL estimate and primary disease-control result are not affected by those specific inconsistencies.
Conflicts of interest and partial support are disclosed, but the article does not state whether ethics approval, waiver, or consent was obtained for the retrospective clinical-record and patient-reported-outcome study.
Flags: 1 declared / 5 total
19 of 19 checkable references verified
21 references in manuscript 2 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The regimen was implemented in routine specialist care with monitoring and rescue-treatment instructions, placing it beyond a conceptual proposal. Retrospective single-center evidence does not yet support deployment as general guidance.
“patients were closely monitored”
AI-generated, human-governed. Something look off? Contact us to request a review.